Figure 7. A DR5-agonistic antibody can also be used to convert the response of T47D and ZR751 breast cancer cells from anti-proliferative to pro-apoptotic.

(A) T47D and ZR751 cells were treated with a vehicle control or ONC201 for 72 hours. Anti-DR5 antibody was added at varying concentrations for four hours and the induction of cell death was assessed using western blot. (B) T47D and ZR751 cells were treated as above and stained with propidium iodide. Specifically, ZR751 cells were treated with 200 and 300 ng/mL anti-DR5 antibody. Flow cytometric analysis of the cells was used to determine the percentage of cells with subG₁ DNA content. Experiments shown in this figure were conducted in triplicate.